Amneal Pharmaceuticals, Inc. Class A (AMRX) Dividend History

Amneal Pharmaceuticals, Inc. Class A (AMRX) is a pharmaceutical company that develops, manufacturers, and distributes generic and specialty medications. Founded in 2013, it focuses on providing affordable healthcare solutions across various therapeutic areas, including CNS, dermatology, and gastrointestinal treatments. The company operates through a diverse portfolio of products and emphasizes innovation, quality, and accessibility in its offerings.

Website: https://www.amneal.com

Dividend History

Amneal Pharmaceuticals, Inc. Class A currently does not pay dividends

Company News

Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada

Knight Therapeutics filed a New Drug Submission for CREXONT®, an innovative extended-release Parkinson's disease treatment, with Health Canada. The drug aims to improve patient treatment by offering longer drug absorption and fewer daily doses.

GlobeNewswire Inc.
Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?

Goldman Sachs initiated coverage on several generic pharmaceutical stocks, highlighting Teva's branded drug growth and biosimilar pipeline as positives, while expressing neutrality on Viatris due to uncertainty around its core business. The firm also initiated Amneal with a Buy rating, citing its strong product pipeline and ability to offset price erosion.

Benzinga

Featured Companies: VTRS
Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall

Bausch's (BHC) first-quarter earnings and sales miss their respective estimates. Its shares fall in response to the results.

Zacks Investment Research

Featured Companies: ANIP BHC
Penny Stocks To Buy? 4 To Watch With Big News This Month

Penny stocks to watch this week The post Penny Stocks To Buy? 4 To Watch With Big News This Month appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

PennyStocks

Featured Companies: DNA FUBO MODD
Why Shares of Amneal Pharmaceuticals Are Plunging Wednesday

The company received a complete response letter from the FDA regarding a Parkinson's disease generic therapy.

The Motley Fool

Page data last updated 07/22/2025 04:50:09 UTC